Nonclinical Pharmacokinetics, Pharmacodynamics, and Translational Model of RO7297089, A Novel Anti-BCMA/CD16A Bispecific Tetravalent Antibody for the Treatment of Multiple Myeloma.
BCMA
NK cell engager
multiple myeloma
pharmacodynamics
pharmacokinetics
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
20 09 2022
20 09 2022
Historique:
received:
27
05
2022
accepted:
11
08
2022
entrez:
20
9
2022
pubmed:
21
9
2022
medline:
24
9
2022
Statut:
epublish
Résumé
RO7297089, an anti-B-cell maturation antigen (BCMA)/CD16A bispecific tetravalent antibody, is being developed as a multiple myeloma (MM) therapeutic. This study characterized nonclinical pharmacokinetics (PK), pharmacodynamics (PD), soluble BCMA (sBCMA), and soluble CD16 (sCD16) changes following administration of RO7297089 to support clinical trials. Unbound and total RO7297089 concentrations were measured in cynomolgus monkeys. RO7297089 exhibited a bi-phasic systemic concentration-time profile, similar to a typical human immunoglobulin 1 antibody. Target engagement by RO7297089 led to a robust increase (~100-fold) in total systemic sBCMA levels and relatively mild increase (~2-fold) in total sCD16 levels. To describe the relationship of nonclinical PK/PD data, we developed a target-mediated drug disposition (TMDD) model that includes the systemic target engagement of membrane BCMA (mBCMA), sBCMA, membrane CD16 (mCD16), and sCD16. We then used this model to simulate the PK/PD relationship of RO7297089 in MM patients by translating relevant PK parameters and target levels, based on the literature and newly generated data such as baseline sCD16A levels. Our model suggested that the impact of TMDD on RO7297089 exposure may be more significant in MM patients due to significantly higher expression levels of both mBCMA and sBCMA compared to healthy cynomolgus monkeys. Based on model simulations, we propose more frequent dosing of RO7297089 compared to regular monthly frequency in the clinic at the beginning of treatment to ensure sustained target engagement. This study demonstrates a translational research strategy for collecting relevant nonclinical data, establishing a TMDD model, and using simulations from this model to inform clinical dose regimens.
Identifiants
pubmed: 36127472
doi: 10.1208/s12248-022-00744-8
pii: 10.1208/s12248-022-00744-8
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100Informations de copyright
© 2022. The Author(s).
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Ca-Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551 .
doi: 10.3322/caac.21551
pubmed: 30620402
Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–75. https://doi.org/10.1038/s41375-019-0435-7 .
doi: 10.1038/s41375-019-0435-7
pubmed: 30858549
pmcid: 6820050
Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37–44. https://doi.org/10.1182/blood-2016-03-705210 .
doi: 10.1182/blood-2016-03-705210
pubmed: 27216216
pmcid: 4937359
Cho SF, Anderson KC, Tai YT. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821. https://doi.org/10.3389/fimmu.2018.01821 .
doi: 10.3389/fimmu.2018.01821
pubmed: 30147690
pmcid: 6095983
Bujarski S, Udd K, Soof C, Chen HM, Spektor T, Safaie T, et al. Changes in serum B-cell maturation antigen levels rapidly predict progression free survival among multiple myeloma patients undergoing new treatment. Cl Lymph Myelom Leuk. 2019;19(10):E173–E4. https://doi.org/10.1016/j.clml.2019.09.290 .
doi: 10.1016/j.clml.2019.09.290
Udd K, Chen HM, Li MJ, Soof CM, Casas C, Etessami S, et al. Changes in serum B-cell maturation antigen levels are a more rapid indicator of therapeutic response or disease progression for patients with multiple myeloma. Blood. 2016;128(22). https://doi.org/10.1182/blood.V128.22.5654.5654 .
Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–38. https://doi.org/10.1182/blood-2013-10-535088 .
doi: 10.1182/blood-2013-10-535088
pubmed: 24569262
pmcid: 4023420
Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380(18):1726–37. https://doi.org/10.1056/NEJMoa1817226 .
doi: 10.1056/NEJMoa1817226
pubmed: 31042825
pmcid: 8202968
Fan F, Zhao WH, Liu J, He AL, Chen YX, Cao XM, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. J Clin Oncol. 2017;35(18). https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA3001 .
Kakiuchi-Kiyota S, Schutten MM, Adedeji AO, Cai H, Hendricks R, Liu L, et al. Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA/CD16a bispecific antibody for the treatment of multiple myeloma. Cancer Res. 2020;80(16_Supplement):4556.
Pahl JHW, Koch J, Gotz JJ, Arnold A, Reusch U, Gantke T, et al. CD16A activation of NK cells promotes NK cell proliferation and memory-like cytotoxicity against cancer cells. Cancer Immunol Res. 2018;6(5):517–27. https://doi.org/10.1158/2326-6066.CIR-17-0550 .
doi: 10.1158/2326-6066.CIR-17-0550
pubmed: 29514797
Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, et al. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. mAbs. 2014;6(3):728-39. https://doi.org/10.4161/mabs.28591 .
Rothe A, Sasse S, Topp MS, Eichenauer DA, Hummel H, Reiners KS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024–31. https://doi.org/10.1182/blood-2014-12-614636 .
doi: 10.1182/blood-2014-12-614636
pubmed: 25887777
pmcid: 4528081
Li X, Ptacek TS, Brown EE, Edberg JC. Fcγ receptors: structure, function and role as genetic risk factors in SLE. Genes Immun. 2009;10(5):380–9. https://doi.org/10.1038/gene.2009.35 .
doi: 10.1038/gene.2009.35
pubmed: 19421223
pmcid: 2830794
Rogers KA, Scinicariello F, Attanasio R. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J Immunol. 2006;177(6):3848–56.
doi: 10.4049/jimmunol.177.6.3848
pubmed: 16951347
Hipp S, Tai YT, Blanset D, Deegen P, Wahl J, Thomas O, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31(8):1743–51. https://doi.org/10.1038/leu.2016.388 .
doi: 10.1038/leu.2016.388
pubmed: 28025583
Li J, Piskol R, Ybarra R, Chen YJ, Li J, Slaga D, et al. CD3 bispecific antibody–induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med. 2019;11(508):eaax8861.
Tarte K, Zhan FH, De Vos J, Klein B, Shaughnessy J. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood. 2003;102(2):592–600. https://doi.org/10.1182/blood-2002-10-3161 .
doi: 10.1182/blood-2002-10-3161
pubmed: 12663452
Kaur S, Liu L, Cortes DF, Shao J, Jenkins R, Mylott WR Jr, Xu K. Validation of a biotherapeutic immunoaffinity-LC–MS/MS assay in monkey serum:‘plug-and-play’across seven molecules. Bioanalysis. 2016;8(15):1565–77.
doi: 10.4155/bio-2016-0117
pubmed: 27396481
Li LZ, Gardner I, Rose R. Incorporating target shedding into a minimal PBPK-TMDD model for mAbs. J Pharmacokinet Phar. 2013;40:S90–S1.
Mager DE, Krzyzanski W. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res. 2005;22(10):1589–96. https://doi.org/10.1007/s11095-005-6650-0 .
doi: 10.1007/s11095-005-6650-0
pubmed: 16180117
Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? mAbs. 2011;3(1):61-6. https://doi.org/10.4161/mabs.3.1.13799 .
Ghermezi M, Li MJ, Vardanyan S, Harutyunyan NM, Gottlieb J, Berenson A, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785–95. https://doi.org/10.3324/haematol.2016.150896 .
doi: 10.3324/haematol.2016.150896
pubmed: 28034989
pmcid: 5395119
Lee L, Bounds D, Paterson J, Herledan G, Sully K, Seestaller-Wehr LM, et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Brit J Haematol. 2016;174(6):911–22. https://doi.org/10.1111/bjh.14145 .
doi: 10.1111/bjh.14145
Sanchez E, Li MJ, Kitto A, Li J, Wang CS, Kirk DT, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Brit J Haematol. 2012;158(6):727–38. https://doi.org/10.1111/j.1365-2141.2012.09241.x .
doi: 10.1111/j.1365-2141.2012.09241.x
Rathi C, Collins J, Struemper H, Opalinska J, Jewell RC, Ferron-Brady G. Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma. CPT Pharmacometrics Syst Pharmacol. 2021;10(8):851–63. https://doi.org/10.1002/psp4.12660 .
doi: 10.1002/psp4.12660
pubmed: 34076364
pmcid: 8376139
Eppler S, Combs D, Henry T, Lopez J, Ellis S, Yi J-H, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans*. Clin Pharmacol Ther. 2002;72:20–32. https://doi.org/10.1067/mcp.2002.126179 .
doi: 10.1067/mcp.2002.126179
pubmed: 12152001
Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. 2016;22(13):3383. https://doi.org/10.1158/1078-0432.CCR-15-2224 .
doi: 10.1158/1078-0432.CCR-15-2224
pubmed: 26960399
Goldstein RL, Goyos A, Li CM, Deegen P, Bogner P, Sternjak A, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020;4(17):4180–94. https://doi.org/10.1182/bloodadvances.2020002565 .
doi: 10.1182/bloodadvances.2020002565
pubmed: 32886754
pmcid: 7479952
Plesner T, et al. A phase I study of RO7297089, a B-cell maturation antigen (BCMA)-CD16a bispecific antibody in patients with relapsed/refractory multiple myeloma (RRMM). In: ASH 2021 Annual Meeting and Exposition. https://ash.confex.com/ash/2021/webprogram/Paper147418.html (2021). Accessed 6 May 2022.